14.91
price up icon2.47%   0.36
after-market アフターアワーズ: 14.88 -0.03 -0.20%
loading
前日終値:
$14.55
開ける:
$14.765
24時間の取引高:
620.74K
Relative Volume:
0.34
時価総額:
$1.78B
収益:
$59.61M
当期純損益:
$-262.14M
株価収益率:
-3.8036
EPS:
-3.92
ネットキャッシュフロー:
$-247.49M
1週間 パフォーマンス:
-3.37%
1か月 パフォーマンス:
+3.54%
6か月 パフォーマンス:
+9.63%
1年 パフォーマンス:
+46.18%
1日の値動き範囲:
Value
$14.74
$14.94
1週間の範囲:
Value
$14.10
$15.78
52週間の値動き範囲:
Value
$7.86
$17.75

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name
名前
Arcutis Biotherapeutics Inc
Name
セクター
Healthcare (1163)
Name
電話
805-418-5006
Name
住所
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Name
職員
342
Name
Twitter
@ArcutisBio
Name
次回の収益日
2024-12-06
Name
最新のSEC提出書
Name
ARQT's Discussions on Twitter

ARQT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ARQT
Arcutis Biotherapeutics Inc
14.91 1.73B 59.61M -262.14M -247.49M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-30 開始されました H.C. Wainwright Buy
2024-08-28 開始されました Jefferies Buy
2024-01-03 アップグレード Mizuho Neutral → Buy
2023-10-26 ダウングレード Mizuho Buy → Neutral
2023-10-13 ダウングレード Goldman Buy → Neutral
2022-09-07 開始されました Needham Buy
2022-03-17 開始されました Goldman Buy
2021-06-30 開始されました Mizuho Buy
2021-05-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-11-09 アップグレード Goldman Neutral → Buy
2020-10-08 開始されました Truist Buy
2020-02-25 開始されました Cantor Fitzgerald Overweight
2020-02-25 開始されました Cowen Outperform
2020-02-25 開始されました Goldman Neutral
2020-02-25 開始されました Guggenheim Buy
すべてを表示

Arcutis Biotherapeutics Inc (ARQT) 最新ニュース

pulisher
04:21 AM

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - The Manila Times

04:21 AM
pulisher
06:10 AM

What analysts say about Arcutis Biotherapeutics Inc. stockFree Investment Community - Autocar Professional

06:10 AM
pulisher
Jul 22, 2025

Arcutis Biotherapeutics Inc. Stock Analysis and ForecastExponential return rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Arcutis Biotherapeutics Inc. a good long term investmentFree Capital Growth Strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Arcutis Biotherapeutics Inc. stock priceAccelerated wealth building - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth - Investing.com India

Jul 21, 2025
pulisher
Jul 20, 2025

(ARQT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 17, 2025

Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study - TipRanks

Jul 17, 2025
pulisher
Jul 15, 2025

Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load? - simplywall.st

Jul 15, 2025
pulisher
Jul 14, 2025

Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise - Investing.com Canada

Jul 14, 2025
pulisher
Jul 14, 2025

Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN

Jul 14, 2025
pulisher
Jul 11, 2025

FDA News and Decisions: Midyear Updates - Dermatology Times

Jul 11, 2025
pulisher
Jul 10, 2025

Arcutis Biotherapeutics Stock Scores RS Rating Upgrade - MSN

Jul 10, 2025
pulisher
Jul 09, 2025

(ARQT) Investment Analysis - news.stocktradersdaily.com

Jul 09, 2025
pulisher
Jul 09, 2025

Arcutis Biotherapeutics - WBFF

Jul 09, 2025
pulisher
Jul 09, 2025

Uncovering Plaque Psoriasis: Exploring New FDA-Approved Topical Treatment - ABC Action News

Jul 09, 2025
pulisher
Jul 04, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 04, 2025
pulisher
Jul 03, 2025

Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating - Investing.com Nigeria

Jul 03, 2025
pulisher
Jul 03, 2025

Arcutis Awards Generous Stock Compensation Package: 14,000 RSUs for Two New Hires - Stock Titan

Jul 03, 2025
pulisher
Jun 27, 2025

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis - Contemporary Pediatrics

Jun 27, 2025
pulisher
Jun 26, 2025

Arcutis Biotherapeutics (ARQT) Gains Strong AAD Recommendation for ZORYVE Cream | ARQT Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

ZORYVE Becomes Only Branded Topical to Earn Strong AAD Recommendation for Atopic Dermatitis - Stock Titan

Jun 26, 2025
pulisher
Jun 25, 2025

Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha

Jun 25, 2025
pulisher
Jun 23, 2025

Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st

Jun 23, 2025
pulisher
Jun 18, 2025

When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 18, 2025

Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance

Jun 18, 2025
pulisher
Jun 17, 2025

Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks

Jun 17, 2025
pulisher
Jun 12, 2025

Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha

Jun 12, 2025
pulisher
Jun 11, 2025

10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Australia

Jun 10, 2025

Arcutis Biotherapeutics Inc (ARQT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
大文字化:     |  ボリューム (24 時間):